Dr. Elizabeth J. Davis
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Cancer
Studies Soft Tissue Sarcoma
18 reported clinical trials
24 drugs studied
About Elizabeth J. Davis
Education:
- Obtained MD from Vanderbilt University School of Medicine in 2009.
- Completed Residency in Internal Medicine at Vanderbilt University Medical Center in 2012.
- Finished Fellowship in Hematology/Oncology at Vanderbilt University Medical Center in 2015.
Experience:
- Specializes in hematology and oncology at Ingram Cancer Center, Vanderbilt University Medical Center.
- Serves as Assistant Professor of Medicine at Vanderbilt University Medical Center.
Area of expertise
1Cancer
Stage IV
Stage III
EWSR1/ATF1 positive
2Soft Tissue Sarcoma
Stage IV
Stage III
EWSR1/ATF1 positive
Affiliated Hospitals
Clinical Trials Elizabeth J. Davis is currently running
Immunotherapy + Chemotherapy
for Soft Tissue Sarcoma
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Adding cabozantinib to the combination of ipilimumab and nivolumab may be better in stopping or slowing the growth of tumor compared to ipilimumab and nivolumab alone in patients with advanced soft tissue sarcoma.
Recruiting1 award Phase 2
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
More about Elizabeth J. Davis
Clinical Trial Related5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Elizabeth J. Davis has experience with
- Pembrolizumab
- INBRX-109
- Atezolizumab
- Olaparib
- 9-ING-41
- Toripalimab
Breakdown of trials Elizabeth J. Davis has run
Cancer
Soft Tissue Sarcoma
Malignant Fibrous Histiocytoma
Soft tissue sarcoma
Bone Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Elizabeth J. Davis specialize in?
Is Elizabeth J. Davis currently recruiting for clinical trials?
Are there any treatments that Elizabeth J. Davis has studied deeply?
What is the best way to schedule an appointment with Elizabeth J. Davis?
What is the office address of Elizabeth J. Davis?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.